RSV seasons ended earlier than usual in 2022-23 and 2023-24, and typical human hMPV circulation patterns have returned since the COVID-19 pandemic.

U.S. Health Secretary Robert F. Kennedy Jr.'s newly revamped vaccine advisory panel voted on Thursday to recommend Americans ...

The Center for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), and its eight new members, met for the first time Thursday after Health and Humans Services ...

Robert F. Kennedy Jr. had fired all 17 members of a key vaccine panel. Now his new panel recommended a new infant RSV vaccine ...

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

CDC advisers recommend Merck's Enflonsia to protect babies from RSV, addressing the leading cause of infant hospitalization ...

What are the effects (benefits and harms) of palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children? Background RSV is the main cause of acute respiratory infections ...

Human respiratory syncytial virus (RSV) is the leading cause of upper and lower respiratory tract infections in pediatric patients worldwide. The severity of RSV infections is greatest in infants and ...

Human induced pluripotent stem cell (iPSC) lines are a promising model for the early phase of human embryonic development. Here, their contribution to the still incompletely understood pathogenesis of ...

Expanded Approval: Moderna’s mRESVIA vaccine is now FDA-approved for adults aged 18–59 years with an increased risk for respiratory syncytial virus (RSV)-related lower respiratory tract disease.; ...

Early estimate of nirsevimab effectiveness for prevention of respiratory syncytial virus–associated hospitalization among infants entering their first respiratory syncytial virus season — New Vaccine ...